Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the quinazoline class of organic compounds. It features a hexahydroquinazoline core substituted with a methyl(3,4,5-trimethoxyphenyl)aminomethyl group and two amino groups at positions 2 and 4. The molecule has defined stereochemistry at positions (2R) and (6S). It is listed as an experimental drug in chemical databases but does not have an assigned therapeutic indication or known mechanism of action in humans. Its structure suggests potential for biological activity through interactions typical of quinazolines—such as kinase inhibition—but no specific pharmacological target or clinical use has been established.[1][9][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2R,6S)-6-{[methyl(3,4,5-trimethoxyphenyl)amino]methyl}-1,2,5,6,7,8-hexahydroquinazoline-2,4-diamine.